Halozyme Therapeutics (HALO) Downgraded by BidaskClub to Hold
Halozyme Therapeutics (NASDAQ:HALO) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a report issued on Tuesday.
HALO has been the subject of a number of other reports. Barclays cut Halozyme Therapeutics from an “overweight” rating to a “hold” rating and increased their price target for the stock from $16.00 to $19.00 in a report on Wednesday, November 22nd. Canaccord Genuity increased their price target on Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets increased their price target on Halozyme Therapeutics from $15.00 to $18.00 and gave the stock a “market perform” rating in a report on Wednesday, November 8th. Piper Jaffray Companies increased their price target on Halozyme Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, October 16th. Finally, Zacks Investment Research cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $18.13.
Shares of Halozyme Therapeutics (NASDAQ:HALO) opened at $18.05 on Tuesday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.46 and a quick ratio of 3.37. Halozyme Therapeutics has a twelve month low of $9.68 and a twelve month high of $19.37.
Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by ($0.04). The company had revenue of $63.73 million during the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The firm’s quarterly revenue was up 100.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.23) earnings per share. equities analysts anticipate that Halozyme Therapeutics will post 0.15 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of HALO. Teacher Retirement System of Texas acquired a new position in Halozyme Therapeutics during the 2nd quarter worth about $129,000. Arrowstreet Capital Limited Partnership acquired a new position in Halozyme Therapeutics during the 2nd quarter worth about $131,000. Prudential Financial Inc. lifted its stake in Halozyme Therapeutics by 8.7% during the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 940 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Halozyme Therapeutics during the 2nd quarter worth about $171,000. Finally, Amalgamated Bank raised its position in Halozyme Therapeutics by 5.3% in the 2nd quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 705 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.